Sars Cov 2 Infection clinical trials

Explore recruiting sars cov 2 infection clinical trials.

Recruiting sars cov 2 infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sars Cov 2 Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4671026-A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE

Bulgaria, Hungary

Phase II and Phase III (Integrated) EU CTIS Study details

Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coronavirus disease 2019 (COVID-19) in adolescents from 12 years to less than 18 years of age.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (DAN-COVID)

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Long-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease

Poland

Phase II and Phase III (Integrated) EU CTIS Study details

TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Sars Cov 2 Infection trials by city

Sars Cov 2 Infection in Toronto Sars Cov 2 Infection in Vancouver Sars Cov 2 Infection in Montreal Sars Cov 2 Infection in Calgary Sars Cov 2 Infection in Edmonton Sars Cov 2 Infection in Ottawa Sars Cov 2 Infection in Winnipeg Sars Cov 2 Infection in Quebec City Sars Cov 2 Infection in Hamilton Sars Cov 2 Infection in Kitchener Sars Cov 2 Infection in London Sars Cov 2 Infection in Halifax Sars Cov 2 Infection in New York Sars Cov 2 Infection in Los Angeles Sars Cov 2 Infection in Chicago Sars Cov 2 Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease